[{"id":"ef9e7260-d9e3-483f-aa0a-3b74c6c79ebc","acronym":"VANGUARD","url":"https://clinicaltrials.gov/study/NCT07469735","created_at":"2026-03-28T01:44:12.900Z","updated_at":"2026-03-28T01:44:12.900Z","phase":"","brief_title":"Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma","source_id_and_acronym":"NCT07469735 - VANGUARD","lead_sponsor":"Huashan Hospital","biomarkers":" IDH1 • IDH2","pipe":"","alterations":" ","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-13"},{"id":"6f7bf383-609e-4543-baf3-bf987cf68486","acronym":"","url":"https://clinicaltrials.gov/study/NCT03728335","created_at":"2023-11-24T19:04:58.043Z","updated_at":"2025-02-25T14:40:02.257Z","phase":"Phase 2","brief_title":"Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation","source_id_and_acronym":"NCT03728335","lead_sponsor":"City of Hope Medical Center","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 01/11/2027","primary_completion_date":" 01/11/2027","study_txt":" Completion: 01/11/2027","study_completion_date":" 01/11/2027","last_update_posted":"2025-02-14"},{"id":"d6b5f034-4f23-41ab-9424-0eeb245d22d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04203316","created_at":"2021-01-18T20:28:43.981Z","updated_at":"2025-02-25T15:11:26.261Z","phase":"Phase 2","brief_title":"Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation","source_id_and_acronym":"NCT04203316","lead_sponsor":"Children's Oncology Group","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/14/2023","start_date":" 08/14/2023","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-13"},{"id":"35a86a04-d158-4bfb-8750-bfb724605cdd","acronym":"P30CA016672","url":"https://clinicaltrials.gov/study/NCT03383575","created_at":"2021-01-18T16:41:48.451Z","updated_at":"2025-02-25T14:37:54.258Z","phase":"Phase 2","brief_title":"Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome","source_id_and_acronym":"NCT03383575 - P30CA016672","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IDH2 • RUNX1 • ASXL1","pipe":" | ","alterations":" IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation","tags":["TP53 • IDH2 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-10"},{"id":"625a8643-bad7-473d-8b71-3b4bd3eac313","acronym":"MPN-RC 119","url":"https://clinicaltrials.gov/study/NCT04281498","created_at":"2021-01-18T20:47:14.678Z","updated_at":"2025-02-25T14:29:04.725Z","phase":"Phase 2","brief_title":"Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","source_id_and_acronym":"NCT04281498 - MPN-RC 119","lead_sponsor":"John Mascarenhas","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2025-02-04"},{"id":"254804cf-c50f-409d-b809-0f0a4043dc18","acronym":"CL1-95032-005","url":"https://clinicaltrials.gov/study/NCT05484622","created_at":"2022-08-02T12:55:57.680Z","updated_at":"2025-02-25T16:18:00.683Z","phase":"Phase 1","brief_title":"Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma","source_id_and_acronym":"NCT05484622 - CL1-95032-005","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Voranigo (vorasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2025-01-14"},{"id":"a154a323-d6ef-4152-926e-c4ab1ae75b5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756777","created_at":"2023-03-06T15:01:58.629Z","updated_at":"2025-02-25T15:36:05.770Z","phase":"Phase 1","brief_title":"A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05756777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation","tags":["FLT3 • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-11-12"},{"id":"12c4bdec-2faf-43d1-a25f-e666a7565100","acronym":"NCI-2022-02837","url":"https://clinicaltrials.gov/study/NCT05282459","created_at":"2022-03-16T15:54:13.299Z","updated_at":"2025-02-25T14:16:45.662Z","phase":"Phase 1/2","brief_title":"Enasidenib in MDS \u0026Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation","source_id_and_acronym":"NCT05282459 - NCI-2022-02837","lead_sponsor":"Stanford University","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-09-26"},{"id":"bdecc9b3-c8fa-4ac1-b2d7-05e45884f6a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04522895","created_at":"2021-01-18T21:39:54.008Z","updated_at":"2025-02-25T14:29:32.125Z","phase":"Phase 2","brief_title":"IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT","source_id_and_acronym":"NCT04522895","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 07/24/2024","primary_completion_date":" 07/24/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2024-09-19"},{"id":"8e4c392a-1d29-432d-a4da-6bb8e1258676","acronym":"AG120-221-C-001","url":"https://clinicaltrials.gov/study/NCT02632708","created_at":"2021-01-17T17:12:58.212Z","updated_at":"2025-02-25T14:36:02.501Z","phase":"Phase 1","brief_title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02632708 - AG120-221-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Tibsovo (ivosidenib) • daunorubicin • Idhifa (enasidenib) • idarubicin hydrochloride • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/31/2015","start_date":" 12/31/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-07-25"},{"id":"1b7433f8-fdf4-4ed8-b6bd-286988acbcd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04521686","created_at":"2021-01-18T21:39:29.090Z","updated_at":"2024-07-02T16:34:37.926Z","phase":"Phase 1","brief_title":"Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT04521686","lead_sponsor":"Eli Lilly and Company","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • LY3410738"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"67ee693c-6b97-4b0f-b34b-6654a4861bbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04603001","created_at":"2021-01-19T20:30:51.296Z","updated_at":"2024-07-02T16:34:58.765Z","phase":"Phase 1","brief_title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT04603001","lead_sponsor":"Eli Lilly and Company","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • LY3410738"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 07/03/2023","primary_completion_date":" 07/03/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"ab92a282-919a-4023-ac7a-0869d1798034","acronym":"NCI-2021-00893","url":"https://clinicaltrials.gov/study/NCT04774393","created_at":"2021-03-01T14:52:29.975Z","updated_at":"2024-07-02T16:34:59.147Z","phase":"Phase 1/2","brief_title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04774393 - NCI-2021-00893","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-06-04"},{"id":"66937713-e1c8-4e82-bb66-47047e56b479","acronym":"IDHENTIFY","url":"https://clinicaltrials.gov/study/NCT02577406","created_at":"2021-03-25T18:30:43.571Z","updated_at":"2024-07-02T16:35:06.839Z","phase":"Phase 3","brief_title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","source_id_and_acronym":"NCT02577406 - IDHENTIFY","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 319","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 03/25/2024","study_completion_date":" 03/25/2024","last_update_posted":"2024-04-30"},{"id":"4649ce0f-4d86-452f-8851-2645fe630f89","acronym":"","url":"https://clinicaltrials.gov/study/NCT05592743","created_at":"2022-10-25T13:56:20.154Z","updated_at":"2024-07-02T16:35:07.258Z","phase":"","brief_title":"Vorasidenib Expanded Access Program","source_id_and_acronym":"NCT05592743","lead_sponsor":"Servier","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-04-26"},{"id":"a900c0e2-07be-4505-9cb0-81a8c6101da5","acronym":"IDEAL Study","url":"https://clinicaltrials.gov/study/NCT03744390","created_at":"2021-01-18T18:20:21.184Z","updated_at":"2024-07-02T16:35:08.558Z","phase":"Phase 2","brief_title":"IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome","source_id_and_acronym":"NCT03744390 - IDEAL Study","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 04/02/2019","start_date":" 04/02/2019","primary_txt":" Primary completion: 02/18/2023","primary_completion_date":" 02/18/2023","study_txt":" Completion: 03/18/2026","study_completion_date":" 03/18/2026","last_update_posted":"2024-04-19"},{"id":"5a752d2a-ae6c-4568-9964-397e60ac09c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02481154","created_at":"2021-01-18T11:56:50.778Z","updated_at":"2024-07-02T16:35:13.092Z","phase":"Phase 1","brief_title":"Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02481154","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 10/17/2022","primary_completion_date":" 10/17/2022","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-03-22"},{"id":"8b030438-7eb9-4387-b341-1cc25b72dae1","acronym":"ViCToRy","url":"https://clinicaltrials.gov/study/NCT05609994","created_at":"2022-11-08T14:56:43.419Z","updated_at":"2024-07-02T16:35:13.515Z","phase":"Phase 1","brief_title":"ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas","source_id_and_acronym":"NCT05609994 - ViCToRy","lead_sponsor":"Katy Peters, MD, PhD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-03-21"},{"id":"0c2abf24-2704-4d9a-bda5-5112c23b6af6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03515512","created_at":"2021-01-18T17:18:10.487Z","updated_at":"2025-02-25T14:26:53.670Z","phase":"Phase 1","brief_title":"IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT03515512","lead_sponsor":"Massachusetts General Hospital","biomarkers":" IDH2 • HLA-B","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 07/17/2018","start_date":" 07/17/2018","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 02/13/2023","study_completion_date":" 02/13/2023","last_update_posted":"2024-03-08"},{"id":"259e072d-8792-4679-9b6b-60d1a376f946","acronym":"I-DATA","url":"https://clinicaltrials.gov/study/NCT05401097","created_at":"2022-06-02T16:58:56.588Z","updated_at":"2024-07-02T16:35:16.613Z","phase":"Phase 2","brief_title":"IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)","source_id_and_acronym":"NCT05401097 - I-DATA","lead_sponsor":"Alice Mims","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-03-04"},{"id":"11040b56-b83a-40c8-b335-611302ea384f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03720366","created_at":"2021-01-18T18:14:03.989Z","updated_at":"2024-07-02T16:35:17.394Z","phase":"Phase 1","brief_title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","source_id_and_acronym":"NCT03720366","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib) • midazolam hydrochloride • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 12/22/2023","study_completion_date":" 12/22/2023","last_update_posted":"2024-02-28"},{"id":"caba8d6b-3a99-4cf4-a5f0-d1c3cfbe3575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03343197","created_at":"2021-01-18T16:30:40.675Z","updated_at":"2024-07-02T16:35:17.668Z","phase":"Phase 1","brief_title":"Study of AG-120 and AG-881 in Subjects With Low Grade Glioma","source_id_and_acronym":"NCT03343197","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" ATRX mutation • IDH1 R132H • IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 08/02/2019","primary_completion_date":" 08/02/2019","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-02-26"},{"id":"ab958479-bd13-4a73-bd48-32331d41cc33","acronym":"NCI-2018-01919","url":"https://clinicaltrials.gov/study/NCT03683433","created_at":"2021-01-18T18:03:37.347Z","updated_at":"2024-07-02T16:35:18.098Z","phase":"Phase 2","brief_title":"Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation","source_id_and_acronym":"NCT03683433 - NCI-2018-01919","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/18/2018","start_date":" 09/18/2018","primary_txt":" Primary completion: 09/20/2025","primary_completion_date":" 09/20/2025","study_txt":" Completion: 09/20/2025","study_completion_date":" 09/20/2025","last_update_posted":"2024-02-22"},{"id":"f25cf478-f7d0-48ec-a823-1e8a5b6955d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04764474","created_at":"2022-03-09T14:53:09.433Z","updated_at":"2024-07-02T16:35:19.376Z","phase":"Phase 1","brief_title":"A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH","source_id_and_acronym":"NCT04764474","lead_sponsor":"Hutchmed","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ranosidenib (HMPL-306)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 02/28/2021","start_date":" 02/28/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-02-14"}]